Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GRFS Relative to the S&P 500

GRFS Relative to the Sector

Seasonal Chart Analysis

Analysis of the Grifols, SA (NASD:GRFS) seasonal charts above shows that a Buy Date of March 18 and a Sell Date of June 11 has resulted in a geometric average return of 7.65% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 16.84% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm’s Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

To download GRFS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GRFS